Timely surgery with antifungal drugs lifesaving for mucormycosis patients: Max Healthcare study

New Delhi: Timely diagnosis along with early surgical and medical management offered better chances of survival to patients suffering from Covid-19 associated mucormycosis, more commonly known as black fungus, finds a study conducted by Max Healthcare here.

The study, based on cases admitted to 11 network hospitals of Max Healthcare between March and July 2021, is posted on the preprint server Medrxiv and is not yet peer reviewed.

Also Read: NPPA fixes ceiling price of Amphotericin B Emulsion Injection to treat Black Fungus

While diabetes and use of steroids emerged as clear risk factors, the study suggested that there is a need to explore other causations for Covid-19 Associated Mucormycosis (CAM) including the direct role played by SARS-CoV-2.

"In moderate and severe cases of Covid-19, the immune system is severely compromised, leading to a severe form of angio-invasive CAM, which has a mortality rate of as high as 80 per cent if a patient goes untreated, or remains untreated long and even after treatment, mortality still could be 40-50 per cent. The fungus thrives in uncontrolled diabetes with ketoacidosis as well as in patients with recent steroid use," Sandeep Budhiraja, Group Medical Director, Max Healthcare, said in a statement.